NHS Logo
Bedfordshire and Luton Joint Formulary
Bedfordshire Hospitals NHS Foundation Trust
Bedfordshire, Luton and Milton Keynes ICB
Formulary Chapter: 1 - Gastro-intestinal system 
Notes:

Any drug not listed on the Formulary should be considered Non-Formulary - Not recommended for prescribing
01.06.07 5HT4 receptor agonists and guanylate cyclase-C receptor agonists
NICE CG61: Irritable Bowel Syndrome NICE CG99: Constipation in children and young people

Linaclotide (Constella▼®)

Amber SPA
Restricted Drug Restricted
Restricted unless in line with JPC guidelines

The use of linaclotide for the symptomatic treatment of severe irritable bowel syndrome with constipation (IBS-C) is supported as a treatment option after an unsuccessful trial of conventional laxatives. (Check diet and compliance with conventional laxatives). Patients must have a confirmed diagnosis of IBS-C prior to treatment with linaclotide.

290mg capsules
BNF BNFc SPC
JPC bulletin 181: Linaclotide for moderate to severe irritable bowel syndrome with constipation

Prucalopride 1mg, 2mg
(Tablets)

RED
Formulary

Unlicensed Indication (Bedford Hospital Use Only)

To be used as a prokinetic required in the bowel preparation regime for CCE in line with NHSE/I guidance.

 

DTC Approved February 2023

BNF BNFc SPC
JPC bulletin: Prucalopride in men (July 2020) NICE TA211: Prucalopride for the treatment of chronic constipation in women

Prucalopride 1mg, 2mg (Resolor ®)
(Tablets)

Amber SPA
Restricted Drug Restricted

 
Patient must have tried at least two different types of laxatives at the highest possible recommended doses, for at least 6 months, and are considering invasive treatment for constipation.

Treatment must be reviewed after 4 weeks.

Approved for use in men at July 2020 JPC Meeting - The Committee approved the addition of Prucalopride to the Joint Formulary for use in men in accordance with the criteria set out in NICE TA 211 for women.

BNF BNFc SPC
JPC bulletin: Prucalopride in men (July 2020) NICE TA211: Prucalopride for the treatment of chronic constipation in women
Classifications
GREEN
May be initiated in any care setting
Amber SPA
Specialist to advise therapy and provide first 28 days supply, continuation in Primary Care
Amber SPIS
Specialist to initiate and stabilise medicine prior to continuation in Primary Care
SCG
To be prescribed as per Shared Care Guidance. If no SCG in place status reverts to red.
RED
Red medicines are designated as specialist only medicines which should only be prescribed by a specialist, usually within secondary care (either due to the requirement for specialist knowledge, long-term monitoring requirements, or restrictions that mean medicine supplies are only available to hospitals).
DNP
A decision has been made either locally and/or nationally not to routinely commission this preparation. Do not prescribe.
SELF
To be purchased over the counter. May be prescribed for chronic, long term conditions or on admission to hospital if essential.